• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » $11.3M awarded to researchers through MRC-AstraZeneca compound collaboration

$11.3M awarded to researchers through MRC-AstraZeneca compound collaboration

November 1, 2012
CenterWatch Staff

The Medical Research Council (MRC) has awarded $11.3 million of funding for 15 research projects awarded through its collaboration with global biopharmaceutical company AstraZeneca, which gave academic researchers unprecedented access to 22 chemical compounds.

Scientists will use the compounds to study a broad range of conditions from common diseases like Alzheimer’s, cancer and lung disease to rarer conditions such as motor neurone disease and muscular dystrophies. Eight of the projects will involve clinical human trials of potential new therapies, and seven will focus on earlier work in laboratory and animal models. All the projects will increase the understanding of human disease and accelerate the search for innovative treatments.

The MRC-AstraZeneca compound collaboration was first announced in December 2011. AstraZeneca made 22 of its chemical compounds available free-of-charge to scientists, who were encouraged to apply for MRC funding to use them in medical research with the ultimate aim of benefitting patients. AstraZeneca had conducted early trials of these compounds and validated their use for future research, but had put them on hold for further development. This collaboration extends the possible application of these compounds for use in new areas.

“The quality of applications we received for the MRC-AstraZeneca collaboration was higher than we could ever have hoped and we are delighted to be funding 15 excellent projects,” said Patrick Johnston, chair of the MRC’s Translational Research Group. “Thanks to the generosity of AstraZeneca, U.K. scientists will be able to carry out medical research that otherwise may never have been possible. Not only will this bring benefits for patients in the form of more effective medicines and a better understanding of disease, but it has also allowed academic researchers to forge new partnerships with industry, which will give rise to future collaboration across the life sciences sector.”

After looking at over 100 expressions of interest, the MRC received 23 full funding proposals. The applications were assessed by the MRC, independently of AstraZeneca through international expert peer review, and the 15 successful proposals were selected on the basis of scientific quality and importance.

The rights to intellectual property generated using the compounds will vary from project to project, but will be equitable and similar to those currently used in academically-led research. AstraZeneca will retain its existing rights relating to the compounds and any new research findings by the academic institution will be owned by the academic institution.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing